Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

Neurolief Ltd.55 enrolled

Overview

This study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relievion™).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Migraine

Interventions

Relievion device- Treatment stimulationDEVICE

1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation

Relievion Device- Sham stimulationDEVICE

1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Males and females Ages of 18 to 65 years old. 2. History of episodic or chronic migraine with or without aura meeting the diagnostic criteria listed in ICHD (International Classification of Headache Disorders)-III beta (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarction). 3. Capable to corporate with the study protocol and to sign an informed consent. Exclusion Criteria: 1. Patients having received Botox treatment in the head region in the prior 4 months. 2. Patients having received supraorbital or occipital nerve blocks in the prior 4 months. 3. History of Medication Overuse Headache. 4. Patients using opioid medication. 5. Allodynia: intolerance to supraorbital and/or occipital neurostimulation that makes the treatment not applicable (the patients will be excluded if they are unable to tolerate the first 10 minutes of neurostimulation). 6. Implanted metal or electrical devices in the head (not including dental implants). 7. Patient having had a previous experience with the Relievion™ device. 8. Patients who have concomitant epilepsy. 9. History of neurosurgical interventions. 10. Patients with implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps. 11. History of drug abuse or alcoholism. 12. Participation in current clinical study or participated in a clinical study within 3 months prior to this study. 13. Skin lesion or inflammation at the region of the stimulating electrodes. 14. Personality or somatoform disorder. 15. Pregnancy or Lactation. 16. Women with child bearing potential without medically acceptable method of contraception. 17. History of cerebrovascular event. 18. Subjects with recent brain or facial trauma (occurred less than 3 months prior to this study). 19. Patients using Cannabis 20. Patients with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters.

Locations (1)

Laniado Medcial Center

Netanya, Israel

Outcomes

Primary Outcomes

Mean change of pain score (measured on a visual analog scale=VAS) at 1 hour compared to baseline

visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable pain

Time frame: 1 hour

Secondary Outcomes

Mean change of pain score (measured by VAS) at 2 hours compared to baseline (if rescue therapy was not used).

visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable painbaseline (if rescue therapy was not used).

Time frame: 2 hours

Mean change of pain score (measured by VAS) at 24 hours compared to baseline (if rescue therapy was not used).

Time frame: 24 hours

Proportion of patients not having required rescue medication within 24 hours

Time frame: 24 hours

Proportion of patients not having required rescue medication at 2 hours compared to baseline.

Proportion of patients not having required rescue medication at 2 hours

Time frame: 2 hours

Proportion of patients pain free at 1,2 and 24 hours from baseline (if rescue therapy was not used).

Time frame: 1, 2, 24 hours

Proportion of "responders" ("responder" is defined as decrease of at least 50% in VAS pain score from baseline) at 1,2 and 24 hours from baseline (if rescue therapy was not used).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.